IgG4-related disease (IgG4-RD) is an increasingly recognized fibro-inflammatory disorder that can lead to end-stage organ damage if left untreated [1]. Glucocorticoids have been historically considered the first-line treatment for IgG4-RD, but flares occur during or after steroid tapering in most patients [1]. In case of disease relapse or multiorgan involvement requiring a more aggressive approach B-cell depletion with rituximab represents an increasingly used effective alternative that offers relevant steroid-sparing advantages [2].
